Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing

Pilocytic astrocytoma (PA) is the most frequent pediatric brain tumor. Activation of the MAPK pathway is well established as the oncogenic driver of the disease. It is most frequently caused by KIAA1549:BRAF fusions, and leads to oncogene induced senescence (OIS). OIS is thought to be a major reason for growth arrest of PA cells in vitro and in vivo, preventing establishment of PA cultures. Hence, valid preclinical models are currently very limited, but preclinical testing of new compounds is urgently needed. We transduced the PA short-term culture DKFZ-BT66 derived from the PA of a 2-year old patient with a doxycycline-inducible system coding for Simian Vacuolating Virus 40 Large T Antigen (SV40-TAg). SV40-TAg inhibits TP53/CDKN1A and CDKN2A/RB1, two pathways critical for OIS induction and maintenance. DNA methylation array and KIAA1549:BRAF fusion analysis confirmed pilocytic astrocytoma identity of DKFZ-BT66 cells after establishment. Readouts were analyzed in proliferating as well as senescent states, including cell counts, viability, cell cycle analysis, expression of SV40-Tag, CDKN2A (p16), CDKN1A (p21), and TP53 (p53) protein, and gene-expression profiling. Selected MAPK inhibitors (MAPKi) including clinically available MEK inhibitors (MEKi) were tested in vitro. Expression of SV40-TAg enabled the cells to bypass OIS and to resume proliferation with a mean doubling time of 45h allowing for propagation and long-term culture. Withdrawal of doxycycline led to an immediate decrease of SV40-TAg expression, appearance of senescent morphology, upregulation of CDKI proteins and a subsequent G1 growth arrest in line with the re-induction of senescence. DKFZ-BT66 cells still underwent replicative senescence that was overcome by TERT expression. Testing of a set of MAPKi revealed differential responses in DKFZ-BT66. MEKi efficiently inhibited MAPK signaling at clinically achievable concentrations, while BRAF V600E- and RAF Type II inhibitors showed paradoxical activation. Taken together, we have established the first patient-derived long term expandable PA cell line expressing the KIAA1549:BRAF-fusion suitable for preclinical drug testing.

[1]  W. Hahn,et al.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.

[2]  M. Herlyn,et al.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. , 2016, Cancer cell.

[3]  Stefan M. Pfister,et al.  Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets , 2016, Acta Neuropathologica.

[4]  M. Berger,et al.  BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas , 2016, Clinical Cancer Research.

[5]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[6]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[7]  S. Braun,et al.  Activation loop phosphorylation regulates B‐Raf in vivo and transformation by B‐Raf mutants , 2016, The EMBO journal.

[8]  Shawn M. Gillespie,et al.  Insulator dysfunction and oncogene activation in IDH mutant gliomas , 2015, Nature.

[9]  L. Zender,et al.  mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype , 2015, Nature Cell Biology.

[10]  M. Kool,et al.  Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma , 2015, Acta neuropathologica communications.

[11]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[12]  David T. W. Jones,et al.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. , 2014, Neuro-oncology.

[13]  P. Stephens,et al.  Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. , 2014, Cancer discovery.

[14]  B. Widemann,et al.  Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs). , 2014 .

[15]  M. Prados,et al.  A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report. , 2014 .

[16]  Tomoyasu Ishikawa,et al.  Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. , 2013, Cancer research.

[17]  Mariko DeWire,et al.  Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma , 2013, Clinical Cancer Research.

[18]  M. Kieran,et al.  New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model , 2013, Clinical Cancer Research.

[19]  Tomoyasu Ishikawa,et al.  Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives. , 2013, Journal of medicinal chemistry.

[20]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[21]  J. Mettetal,et al.  Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC. , 2013 .

[22]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[23]  Volker Hovestadt,et al.  Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma , 2013, Acta Neuropathologica.

[24]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[25]  A. Resnick,et al.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.

[26]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[27]  T. Pietsch,et al.  Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. , 2012, Neuro-oncology.

[28]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[29]  A. von Deimling,et al.  Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.

[30]  G. Smyth,et al.  Camera: a competitive gene set test accounting for inter-gene correlation , 2012, Nucleic acids research.

[31]  H. Horlings,et al.  Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. , 2012, Genes & development.

[32]  T. MacDonald,et al.  Identification of transcriptional regulatory networks specific to pilocytic astrocytoma , 2011, BMC Medical Genomics.

[33]  S. Pfister,et al.  Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas , 2011, Clinical Cancer Research.

[34]  G. Nikkhah,et al.  BRAF Activation Induces Transformation and Then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model , 2011, Clinical Cancer Research.

[35]  David T. W. Jones,et al.  An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. , 2011, The Journal of clinical investigation.

[36]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[37]  Jo-Fen Liu,et al.  A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702). , 2010, Neuro-oncology.

[38]  D. Peeper,et al.  The essence of senescence. , 2010, Genes & development.

[39]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[40]  P. Northcott,et al.  HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth , 2010, Clinical Cancer Research.

[41]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[42]  M. Pawlita,et al.  High-throughput detection and multiplex identification of cell contaminations , 2009, Nucleic acids research.

[43]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[44]  A. L. Fridman,et al.  Critical pathways in cellular senescence and immortalization revealed by gene expression profiling , 2008, Oncogene.

[45]  D. Peeper,et al.  Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network , 2008, Cell.

[46]  G. Reifenberger,et al.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.

[47]  J. Davis.  Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .

[48]  C. Johannessen,et al.  A negative feedback signaling network underlies oncogene-induced senescence. , 2006, Cancer cell.

[49]  J. Rutka,et al.  The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. , 2006, Neoplasia.

[50]  R. Reddel,et al.  The first molecular details of ALT in human tumor cells. , 2005, Human molecular genetics.

[51]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[52]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[53]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[54]  A. Lloyd,et al.  Milestones in cell division: Cell senescence and cancer , 2001, Nature Reviews Cancer.

[55]  J. Sedivy,et al.  Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. , 1999, Cancer research.

[56]  J. Koudstaal,et al.  The proliferative potential of the pilocytic astrocytoma: The relation between MIB-1 labeling and clinical and neuro-radiological follow-up , 1998, Journal of Neuro-Oncology.

[57]  S. Benchimol,et al.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span , 1998, Current Biology.

[58]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[59]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[60]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[61]  C Roskelley,et al.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[62]  P. Friedman,et al.  Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. , 1992, Genes & development.

[63]  Wen-Hwa Lee,et al.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene , 1988, Cell.

[64]  A. Levine,et al.  Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells , 1981, Molecular and cellular biology.

[65]  C. Stiles,et al.  Dual control of cell growth by somatomedins and platelet-derived growth factor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Herlyn,et al.  An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. , 2016, Cancer cell.

[67]  Jill S. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.

[68]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[69]  B. Scheithauer,et al.  Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.